## Abstract The role of leukapheresis was explored in the management of anaemia and thrombocytopenia complicating the accumulation of lymphoid cells in patients with chronic lymphocytic leukaemia and lymphoma. The aim of this study was to determine the efficiency of this procedure in correcting the
Chromosome studies in patients with T-CLL chronic lymphocytic leukemia and expansions of granular lymphocytes
β Scribed by B. Dallapiccola; G. Alimena; L. Chessa; R. Gastaldi; G. De Rossi; G. Semenzato; I. Quinti; F. Pandolfi
- Publisher
- John Wiley and Sons
- Year
- 1984
- Tongue
- French
- Weight
- 605 KB
- Volume
- 34
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
Chromosome analyses were carried out in eight patients with lymphoproliferative disorders of mature T and NK cells. Three cases were characterized by an abnormal expansion of granular lymphocytes (GL), one by a lymphoma of GL with leukemic spread, and four by an OKT4βTβCLL In four patients cytogenetic studies were performed on bone marrow cells; in seven patients peripheral blood lymphocytes were examined by either direct preparations or PHAβstimulated cultures. Six patients displayed a normal karyotype. Two cases belonging to the OKT4βTβCLL group had a chromosome number ranging from 44 to 47, with multiple numerical and structural clonal anomalies. Clonal anomalies could be a feature of patients with the more aggressive clinical course.
π SIMILAR VOLUMES
In a pilot study of the combination of epirubicin and chlorambucil in the treatment of chronic lymphocytic leukemia (CLL), 10 patients with advanced or progressive disease were treated in four centres. Up to a total of 15 courses in individual patients were given. Toxicity was relatively mild with n
## Abstract ## BACKGROUND One of the mechanisms of action of cladribine is the inhibition of DNA repair of damage caused by radiation, alkylating agents, or other drugs. To determine its antitumor activity in combination with cyclophosphamide, we initiated a Phase II trial of the two agents in pat